Abstract
Background Human male infertility has a notable genetic component, including well established diagnoses like Klinefelter syndrome, Y-chromosome microdeletions, and monogenic causes. Approximately 4% of all infertile men are now diagnosed with a genetic cause, but a vast majority (60-70%) remain without a clear diagnosis and are classified as unexplained. This is likely in large part due to a delay in the field adopting next generation sequencing technologies, and the absence of clear statements from leaders in the field as to what constitutes a validated cause of human male infertility (the current paper aims to address this). Fortunately, there has been a significant increase in the number of male infertility next generation sequencing studies. These have revealed a considerable number of novel gene-disease relationships (GDRs), which each require stringent assessment to validate the strength of genotype-phenotype associations. To definitively assess which of these GDRs are clinically relevant, the International Male Infertility Genomics Consortium (IMIGC) has identified the need for a systematic review and a comprehensive overview of known male infertility genes and an assessment of the extent of evidence for reported GDRs.
Objective and rationale In 2019, the first standardised clinical validity assessment of monogenic causes of male infertility was published. Here, we provide a comprehensive update of the subsequent 1.5 years, employing the joint expertise of the IMIGC to systematically evaluate all available evidence (as of July 1st, 2020) for monogenic causes of isolated or syndromic male infertility, endocrine disorders or reproductive system abnormalities affecting the male sex organs. In addition, we systematically assessed the evidence for all previously reported possible monogenic causes of male infertility, using a framework designed for a more appropriate clinical interpretation of disease genes.
Search methods We performed a literature search according to the PRISMA guidelines up until the 1st of July 2020 for publications in English, using search terms related to “male infertility” in combination with the word “genetics” in PubMed. Next, the quality and the extent of all evidence supporting selected genes was assessed using an established and standardised scoring method. We assessed the experimental quality, patient phenotype assessment, and functional evidence based on gene expression, mutant in vitro cell and in vivo animal model phenotypes. A final score was used to determine the clinical validity of each GDR, as expressed by the following five categories: no evidence, limited, moderate, strong or definitive. Variants were also reclassified according to the ACMG-AMP guidelines and were recorded in spreadsheets for each GDR, which is available at imigc.org.
Outcomes The primary outcome of this review was an overview of all known GDRs for monogenic causes of human male infertility and their clinical validity. We identified a total of 120 genes that were moderately, strongly or definitively linked to 104 infertility phenotypes.
Wider implications Our systematic review summarises and curates all currently available evidence to reveal the strength of GDRs in male infertility. The existing guidelines for genetic testing in male infertility cases are based on studies published 25 years ago, and an update is far past due. The insights generated in the current review will provide the impetus for an update of existing guidelines, will inform novel evidence-based genetic testing strategies used in clinics, and will identify gaps in our knowledge of male infertility genetics. We discuss the relevant international guidelines regarding research related to gene discovery and provide specific recommendations to the field of male infertility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Health and Medical Research Council APP1120356 to MKOB, JAV, DFC and KIA The Netherlands Organisation for Scientific Research (918-15-667) to JAV as well as an Investigator Award in Science from the Wellcome Trust (209451) to JAV German Research Foundation sponsored Clinical Research Unit Male Germ Cells: from Genes to Function (DFG, CRU326) to CF and FT National Institutes of Health: Genomics of Spermatogenic Impairment (R01HD078641) to DFC and KIA Spanish Ministry of Health Instituto Carlos III-FIS-FEDER (Grant number: PI17/01822 PI20/01562) to AR-E and CK
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA for this study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available upon request at brendan.houston{at}unimelb.edu.au